secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001193125-24-241092
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience Phase 2b trial of ALTO-100 for MDD fails primary endpoint
---------------------------------------------------------------------------

- ALTO-100 did not show statistically significant improvement on MADRS vs placebo in biomarker-defined MDD patients.
- Favorable safety and tolerability; no new signals; common AEs headache, nausea, abnormal dreams at rates similar to placebo.
- ALTO-100 also in Phase 2b for bipolar depression; cash expected to fund operations into 2027 with other readouts in H1 2025.
- Company will analyze full dataset to determine next steps for ALTO-100 in MDD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000119312524241092/0001193125-24-241092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000119312524241092/d876702d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-241092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer